Speaking with Olon CEO Paolo Tubertini, his commitment to the promise of generics is clear. Several times during the chief executive’s conversation with Generics Bulletin, he reiterates the importance of the active pharmaceutical ingredient specialist being able to offer “quality and affordable medicine” as part of the generics industry, describing this principle as much in terms of a societal necessity as a business objective.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?